ERBB2 and breast carcinoma: The combination of cytotoxic chemotherapy, radiotherapy, and Anti-HER2 therapy (Trastuzumab) administered to patients with HER2 -positive breast cancer poses a significant cardiotoxic risk, particularly of left ventricular dysfunction and heart failure [8].